Every 424B that BioRestorative Therapies, Inc. (BRTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BRTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRTX filings page.
Registration covers up to 15,285,715 shares of common stock underlying outstanding warrants. This prospectus registers 14,285,715 shares issuable upon exercise of Common Stock Warrants (exercise price $0.35) and 1,000,000 shares issuable upon exercise of Placement Agent Warrants (exercise price $0.4375), each exercisable until February 13, 2031. The filing states 25,478,170 shares outstanding as of April 28, 2026 and a post‑exercise share count of up to 40,763,885 assuming full exercise. The company estimates gross proceeds of $5,437,500 if all warrants are exercised for cash and discloses a cashless exercise feature if registration is not effective.
BioRestorative Therapies is conducting a primary offering of up to 14,285,715 Units at $0.35 per Unit, targeting gross proceeds of about $5 million. Each Unit includes one share of common stock (or one pre-funded warrant) plus one five-year common stock warrant exercisable at $0.35.
The company expects net proceeds of about $4.4 million after fees and expenses, to fund its Phase 2 BRTX-100 disc/spine trial, ThermoStem metabolic program, expansion of its biocosmeceutical platform, and general corporate purposes. There is no minimum offering amount, no escrow, and sales are on a reasonable best efforts basis through Rodman & Renshaw.
Shares outstanding were 9,046,242 as of February 11, 2026, and could rise to up to 23,331,957 if the maximum number of Units is sold, assuming no pre-funded warrants are issued and no warrants are exercised. The prospectus highlights a large accumulated deficit, ongoing losses, and substantial doubt about the company’s ability to continue as a going concern without additional financing.
BioRestorative Therapies, Inc. is registering up to 508,592 shares of common stock for resale by existing securityholders. These shares are issuable upon exercise of outstanding warrants and may be sold over time on the Nasdaq Capital Market or in private transactions at market, fixed, or negotiated prices.
The company reports 8,876,242 shares of common stock outstanding as of November 17, 2025. BioRestorative will not receive any proceeds from the resale of shares by the selling securityholders, but would receive up to $1,398,628 in gross proceeds if all related warrants are exercised at the $2.75 per share exercise price. The prospectus highlights that an investment in the stock involves a high degree of risk and that the most recent audited financial statements include an auditor’s explanatory paragraph about the company’s ability to continue as a going concern.